HOLON,Israel, November 3, 2016
/PRNewswire/ --
November 3,
2016 - Compugen Ltd. (NASDAQ: CGEN) will host an R&D Day
in New York City on Wednesday, December 7, 2016, from 9:00 am to 11:00 am ET. A live webcast of the
event will be available via the Investors section of Compugen's
website at http://www.cgen.com. An audio replay of the meeting will
also be available for approximately three months following the
meeting on the Company's website.
The R&D Day will focus on the Company's immuno-oncology
pipeline, which has been generated through the use of the Company's
unique in silico predictive target discovery
infrastructure. The event will also feature a presentation by
Professor Drew Pardoll, M.D., Ph.D.,
Abeloff Professor of Oncology, Medicine, Pathology, and Molecular
Biology and Genetics at Johns Hopkins
University of Medicine, and Director of the Bloomberg~Kimmel
Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer
Center, Johns Hopkins. Prof. Pardoll is the Chairman of
Compugen's Scientific Advisory Board and a member of the Board of
Directors of Compugen USA Inc.,
Compugen's wholly-owned US subsidiary.
Anat Cohen-Dayag, Ph.D.,
President and Chief Executive Officer of Compugen, stated, "We are
very pleased to host an R&D Day focusing on multiple programs
in our early-stage immuno-oncology pipeline. We believe that this
event, together with new CGEN-15029 program data to be presented
next week at the Annual Meeting of the Society for Immunotherapy of
Cancer, will demonstrate to our shareholders the substantial
medical and commercial potential of our Company's programs."
About Compugen
Compugen is a leading therapeutic discovery company utilizing
its broadly applicable predictive discovery infrastructure to
identify novel drug targets and develop first-in-class biologics.
The primary focus of the Company's current pipeline is on immune
checkpoint target candidates discovered by the Company, potentially
providing the basis for a next wave of therapeutics for cancer
immunotherapy. Compugen's business model is based on selectively
entering into collaborations for its novel target candidates and
drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Israel, with
R&D facilities in Israel and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company's novel target candidates. For additional information,
please visit Compugen's corporate website at
http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," and "intends," and describe opinions about future
events. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks:
Compugen's business model is substantially dependent on entering
into collaboration agreements with third parties, and Compugen may
not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.